This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $416,165 to the University of Richmond to investigate the role of the Sodalis glossinidius bacterium in enabling tsetse flies to thrive on blood meals and potentially transmit African trypanosomes, the causative agents of human and animal African trypanosomiasis. The key research goals are to: 1) Screen Sodalis glossinidius transposon libraries...
This federal Project Grant award, totaling $791,864 and running from December 1, 2024 to November 30, 2029, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The primary goal of the research project is to identify the molecular factors that control chromatin organization and gene regulation in the Plasmodium falciparum parasite, the causative agent of the most severe form of human malaria....
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to examine the regulation of RNA editing in two life cycle stages of the protozoan parasite Trypanosoma brucei. The $453,429 award to Texas A&M AgriLife Research aims to gain insights into the key proteins and mechanisms that control differential RNA editing across the parasite's...
This federal Project Grant award of $7,105,240 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to develop an HIV vaccine regimen that elicits cooperative interactions between HIV envelope fusion peptide-directed antibodies and follicle-homing helper and cytotoxic T cells. The three-project program will examine humoral responses and follicular T cells in people receiving...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $102,600 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the College of Health Sciences at the University of Ghana. The grant, awarded on July 1, 2024, will fund research to compare sampling methods for the invasive Anopheles stephensi mosquito and other native malaria vectors in Ghana, as well as determine the extent of spread and population dynamics of this invasive mosquito...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $520,809 to Rosalind Franklin University of Medicine & Science to conduct research on the role of TAM receptors in modulating humoral immunity against parasitic infections, such as malaria. The research aims to identify molecular and cellular immune mechanisms that contribute to the suboptimal immune...
This $153,512 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand and overcome immune evasion mechanisms used by Plasmodium parasites, the causative agents of malaria. The research aims to characterize the memory B cell response to the circumsporozoite protein (CSP) antigen, which is the target of currently deployed malaria vaccines, in order to identify...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $269,054 to the University of California, Merced to conduct research on mechanisms that determine disease outcome following primary infection with the Toxoplasma gondii parasite. The research aims to leverage the Collaborative Cross mouse panel and parasite genetics to dissect novel host-parasite interactions...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $700,288 to the University of South Florida (USF) to conduct research aimed at identifying genetic factors associated with gametocyte development in the malaria parasite Plasmodium falciparum. The research leverages USF's expertise in gametocyte biology, computational genomics, and phenotype comparisons to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to characterize a novel cytoskeletal protein, PFFIG, in the malaria parasite Plasmodium falciparum. The $207,170 grant, awarded on May 29, 2024, will enable the primary awardee, President and Fellows of Harvard College/Harvard Medical School, to use inducible knockout systems and advanced microscopy...
This federal Project Grant award of $942,886 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to investigate trypanosome cAMP signaling and its role in parasite-vector interactions for the African trypanosomiasis disease transmitted by the tsetse fly. The primary awardee, the University of California, Los Angeles (UCLA), is leading a multidisciplinary research effort to: 1) identify tsetse fly-derived factors that modulate trypanosome chemotaxis, 2) define parasite cAMP effector genes responsible for migration from the tsetse midgut to proventriculus, and 3) characterize parasite receptors that perceive chemotactic signals in the fly. This research aims to increase understanding of parasite-vector interactions and identify potential targets for transmission-blocking agents. The award includes a sub-grant to Yale University to provide expertise in tsetse fly biology and trypanosome transmission processes to support the project activities.